Reactivation of Silenced WT1 Transgene by Hypomethylating Agents - Implications for in vitro Modeling of Chemoimmunotherapy

키워드

참고문헌 (37)

1. Roddie C, "Donor lymphocyte infusion following allogeneic hematopoietic stem cell transplantation", Expert Opin Biol Ther, 11, pp.473~487 (2011)
2. Cheever MA, "The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research", Clin Cancer Res, 15, pp.5323~5337 (2009)
3. Sugiyama H, "WT1 (Wilms􀙗 tumor gene 1): biology and cancer immunotherapy", Jpn J Clin Oncol, 40, pp.377~387 (2010)
4. Menssen HD, "Detection by monoclonal antibodies of the Wilms􀙗 tumor (WT1) nuclear protein in patients with acute leukemia", Int J Cancer, 70, pp.518~523 (1997)
5. Baird PN, "Expression of the Wilms􀙗 tumor gene(WT1) in normal hemopoiesis", Exp Hematol, 25, pp.312~320 (1997)
6. Yamagami T, "Growth inhibition of human leukemic cells by WT1 (Wilms tumor gene) antisense oligodeoxynucleotides: implications for the involvement of WT1 in leukemogenesis", Blood, 87, pp.2878~2884 (1996)
7. Scheibenbogen C, "CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia", Blood, 100, pp.2132~2137 (2002)
8. Rezvani K, "T-cell responses directed against multiple HLA-A*0201-restricted epitopes derived from Wilms' tumor 1 protein in patients with leukemia and healthy donors: identification, quantification, and characterization", Clin Cancer Res, 11, pp.8799~8807 (2005)
9. Ohminami H, "HLA class I-restricted lysis of leukemia cells by a CD8(＋) cytotoxic T-lymphocyte clone specific for WT1 peptide", Blood, 95, pp.286~293 (2000)
10. Mailänder V, "Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematological or renal toxicity", Leukemia, 18, pp.165~166 (2004)
11. Rezvani K, "Leukemia-associated antigen- specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies", Blood, 111, pp.236~242 (2007)
12. Van Tendeloo VF, "Induction of complete and molecular remissions in acute myeloid leukemia by Wilms tumor 1 antigen-targeted dendritic cell vaccination", Proc Natl Acad Sci U S A, 107, pp.13824~13829 (2010)
13. Keilholz U, "A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS", Blood, 113, pp.6541~6548 (2009)
14. Kim YJ, "Potential role of adoptively transferred allogeneic WT1-specific CD4+ and CD8+ T lymphocytes for the sustained remission of refractory AML", Bone Marrow Transplant, 45, pp.597~599 (2010)
15. Van Driessche A, "Active specific immunotherapy targeting the Wilms􀙗 tumor protein 1 (WT1) for patients with hematological malignancies and solid tumors: lessons from early clinical trials", Oncologist, 17, pp.250~259 (2012)
16. Buckler AJ, "Isolation, characterization, and expression of the murine Wilms􀙗 tumor gene (WT1) during kidney development", Mol Cell Biol, 11, pp.1707~1712 (1991)
17. Fraizer GC, "Expression of the tumor suppressor gene WT1 in both human and mouse bone marrow", Blood, 86, pp.4704~4706 (1995)
18. Oka Y, "Cancer immunotherapy targeting Wilms tumor gene WT1 product", J Immunol, 164, pp.1873~1880 (2000)
19. Houdebine LM, "Transgenic animal bioreactors", Transgenic Res, 9, pp.305~320 (2000)
20. Migliaccio AR, "Stable and unstable transgene integration sites in the human genome: extinction of the Green Fluorescent Protein transgene in K562 cells", Gene, 256, pp.197~214 (2000)
21. Cedar H, "DNA methylation and gene activity", Cell, 53, pp.3~4 (1988)
22. Challita PM, "Lack of expression from a retroviral vector after transduction of murine hematopoietic stem cells is associated with methylation in vivo", Proc Natl Acad Sci U S A, 91, pp.2567~2571 (1994)
23. Hoeben RC, "Inactivation of the Moloney murine leukemia virus long terminal repeat in murine fibroblast cell lines is associated with methylation and dependent on its chromosomal position", J Virol, 65, pp.904~912 (1991)
24. Jaenisch R, "Treatment of mice with5-azacytidine efficiently activates silent retroviral genomes indifferent tissues", Proc Natl Acad Sci U S A, 82, pp.1451~1455 (1985)
25. Rosenfeld C, "WT1 in acute leukemia, chronic myelogenous leukemia and myelodysplastic syndrome: therapeutic potential of WT1 targeted therapies", Leukemia, 17, pp.1301~1312 (2003)
26. Lake RA, "Immunotherapy and chemotherapy-- a practical partnership", Nat Rev Cancer, 5, pp.397~405 (2005)
27. Kim HS, "Dendritic cell vaccine in addition to FOLFIRI regimen improve antitumor effects through the inhibition of immunosuppressive cells in murine colorectal cancer model", VACCINE, 28(49), pp.7787~7796, ELSEVIER SCI LTD
28. Parikh SA, "Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia", Blood, 118, pp.2062~2068 (2011)
29. Guo ZS, "De novo induction of a cancer", testis antigen by 5-aza-2'-deoxycytidine augments adoptive immunotherapy in a murine tumor model, 2006, pp.66, 1105~1113
30. Fonsatti E, "Functional up-regulation of human leukocyte antigen class I antigens expression by 5-aza-2'-deoxycytidine in cutaneous melanoma: immunotherapeutic implications", Clin Cancer Res, 13, pp.3333~3338 (2007)
31. Sigalotti L, "5-Aza-2'-deoxycytidine (decitabine) treatment of hematopoietic malignancies: a multimechanism therapeutic approach?", Blood, 101, pp.4644~4646 (2003)
32. Choi J, "In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia", Blood, 116, pp.129~139 (2010)
33. Goodyear O, "Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia", Blood, 116, pp.1908~1918 (2010)
34. Gaiger A, "Immunity to WT1 in the animal model and in patients with acute myeloid leukemia", Blood, 96, pp.1480~1489 (2000)
35. Hollenbach PW, "A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines", PLoS One, 5, pp.1~10 (2010)
36. Grassi G, "Inhibitors of DNA methylation and histone deacetylation activate cytomegalovirus promoter-controlled reporter gene expression in human glioblastoma cell line U87", Carcinogenesis, 24, pp.1625~1635 (2003)
37. Swindle CS, "Mechanisms that regulate silencing of gene expression from retroviral vectors", J Hematother Stem Cell Res, 11, pp.449~456 (2002)

관련 논문AI추천